Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
Biomea Fusion (BMEA) has announced a conference call and webcast scheduled for Tuesday, December 17, 2024, at 8:00 am EST to present topline results from COVALENT-111, their Phase II trial of icovamenib in patients with type 2 diabetes. The company, which focuses on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, will make the webcast available to registered attendees through their investor relations website, with a replay available afterward.
Biomea Fusion (BMEA) ha annunciato una conferenza telefonica e un webcast programmati per martedì 17 dicembre 2024, alle 8:00 EST, per presentare i risultati preliminari dello studio COVALENT-111, il loro trial di Fase II su icovamenib in pazienti con diabete di tipo 2. L'azienda, che si concentra sullo sviluppo di piccole molecole covalenti orali per il diabete, l'obesità e i tumori geneticamente definiti, renderà disponibile il webcast agli atti registrati attraverso il loro sito web per le relazioni con gli investitori, con una replica disponibile successivamente.
Biomea Fusion (BMEA) ha anunciado una conferencia telefónica y un webcast programados para el martes 17 de diciembre de 2024, a las 8:00 am EST, para presentar los resultados preliminares de COVALENT-111, su ensayo de fase II de icovamenib en pacientes con diabetes tipo 2. La empresa, que se enfoca en el desarrollo de pequeñas moléculas covalentes orales para la diabetes, la obesidad y los cánceres definidos genéticamente, hará que el webcast esté disponible para los asistentes registrados a través de su sitio web de relaciones con inversores, con una repetición disponible más tarde.
Biomea Fusion (BMEA)는 2024년 12월 17일(화) 오전 8:00 EST에 예정된 전화 회의 및 웹캐스트를 발표하며, COVALENT-111의 주요 결과를 발표할 예정입니다. 이 연구는 제2형 당뇨병 환자에서 icovamenib에 대한 2상 시험입니다. 당뇨병, 비만 및 유전적으로 정의된 암을 위한 경구용 공유 결합 소분자를 개발하는 데 주력하는 이 회사는 투자자 관계 웹사이트를 통해 등록된 참석자에게 웹캐스트를 제공하며, 이후 재생 기능도 제공할 것입니다.
Biomea Fusion (BMEA) a annoncé une conférence téléphonique et un webcast prévus pour le mardi 17 décembre 2024, à 8h00 EST, afin de présenter les résultats préliminaires de COVALENT-111, leur essai de phase II sur l'icovamenib chez les patients atteints de diabète de type 2. L'entreprise, qui se concentre sur le développement de petites molécules covalentes orales pour le diabète, l'obésité et les cancers définis génétiquement, mettra le webcast à la disposition des participants inscrits via son site de relations investisseurs, avec une rediffusion disponible par la suite.
Biomea Fusion (BMEA) hat eine Telefonkonferenz und einen Webcast für Dienstag, den 17. Dezember 2024, um 8:00 Uhr EST angekündigt, um die vorläufigen Ergebnisse von COVALENT-111, ihrer Phase-II-Studie zu icovamenib bei Patienten mit Typ-2-Diabetes, vorzustellen. Das Unternehmen, das sich auf die Entwicklung von oralen kovalenten kleinen Molekülen zur Behandlung von Diabetes, Fettleibigkeit und genetisch definierten Krebserkrankungen konzentriert, wird den Webcast für registrierte Teilnehmer über seine Investor-Relations-Website zur Verfügung stellen, mit einer späteren Wiederholung.
- None.
- None.
Tuesday, December 17, 2024 at 8:00 am EST
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company’s Phase II trial of icovamenib in patients with type 2 diabetes.
Conference Call and Webcast Details
Webcast of Biomea’s investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to registered attendees under the Investors and Media section of the company’s website at https://investors.biomeafusion.com/news-events/events. A replay of the presentation will be archived on Biomea’s site following the event.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Ramses Erdtmann
COO & President of Biomea Fusion
re@biomeafusion.com
FAQ
When will Biomea Fusion (BMEA) announce COVALENT-111 Phase II trial results?
What is the purpose of Biomea's COVALENT-111 Phase II trial?
How can investors access Biomea's (BMEA) COVALENT-111 trial results webcast?
What therapeutic areas does Biomea Fusion (BMEA) focus on?
